×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Readout Newsletter: Vertex, Leqembi, Eisai, and Biogen
STAT
Today's biotech news Vertex's gene therapy, real-world prescriptions of Leqembi, and Zenas BioPharma's immunology.
9 hours ago
Building a Bold Future: A Discussion with a Biogen Brand Lead
Biogen
Kevin Conway, a brand lead for SMA marketing, discusses his professional background, what attracted him to Biogen, and the skills someone...
5 days ago
Biogen tops profit estimates as cost cuts take hold, Alzheimer's drug Leqembi launch picks up
CNBC
Biogen reported first-quarter profit that topped estimates as the company's cost-cutting efforts took hold and sales of its closely watched...
2 weeks ago
Biogen plots 30% Leqembi field force bump, omnichannel campaigns as launch enters new phase
Fierce Pharma
Biogen and Eisai are ready to ramp up their Leqembi sales and marketing push. After a slow start, Biogen is now planning to grow its U.S....
2 weeks ago
Biogen to shut down controversial Alzheimer's drug Aduhelm
AP News
Biogen said that it will end a study of the drug needed for full approval from the Food and Drug Administration, and it will stop sales of...
3 months ago
Biogen discontinues Alzheimer’s medication Aduhelm
CNN
The Alzheimer's medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer's medication,...
3 months ago
Biogen Stock Surges After Two Notable Products Walloped Sales Expectations
Investor's Business Daily
Two of Biogen's newest drugs walloped first-quarter sales expectations on Wednesday, and helped Biogen stock rocket.
2 weeks ago
June 14th Options Now Available For Biogen (BIIB)
Nasdaq
Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the June 14th expiration. At Stock Options Channel,...
4 days ago
Biogen CMO heads for the exits
Fierce Biotech
Biogen's CMO Maha Radhakrishnan departs, leaving behind a legacy in Alzheimer's drug development ... Biogen Chief Medical Officer and Head of...
1 month ago
Biogen Abandons Its Controversial Alzheimer's Drug Aduhelm
The New York Times
Biogen Abandons Its Controversial Alzheimer's Drug Aduhelm. The pharmaceutical company will give up its ownership rights to the drug and stop a...
3 months ago